Claris Lifesciences has received approval from the Ministry of Health (MoH), Russia, to market two more anti-infectives, namely Fluconazole IV 100 ml. and Levofloxacin IV 100 ml.
Fluconazole is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections, whereas Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that is used to treat a broad range of infections. With the total pharmaceutical market size estimated at $11.2 billion and estimated to grow at 12-15 per cent CAGR, Russia is one of the largest and fastest growing pharmaceutical markets in the world. The generic market size in Russia is estimated to be at $3.5 billion.
With these two new approvals, Claris now has a basket of four major anti-infective products for Russia, including existing approved products, namely, Ciprofloxacin IV and Metronidazole IV. The total market size of these four parental products is estimated to be $53 million.
